Clinical Trial Update: Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients [Phase 1]

View source ↗

Summary

Phase 1 study reporting safety and pharmacokinetics of TAP311 in patients with dyslipidemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• TAP311

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Dyslipidaemia | Phase 1 | Status: COMPLETED